BCLI · Brainstorm Cell Therapeutics Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“Such conditions raise substantial doubts about the Company’s ability to continue as a going concern. Management’s plan includes raising funds from outside potential investors, however, as mentioned above, there is no assurance such funding will be available to the Company or that it will be obtained on terms favorable to the Company or will provide the Company with sufficient funds to meet its objectives.”View the 10-Q filed Aug 14, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.48M | $4.18M | $4.65M | $10.75M | $13.96M | $15.24M | $22.33M | $17.2M | $8.29M | $977K | $2.25M | $4.95M | $4.77M | $2.92M | $1.77M | $1.69M | $1.05M | — | — | — | |
| $6.47M | $5.78M | $7.04M | $10.69M | $10.87M | $9.3M | $9.36M | $5.8M | $5.77M | $4.02M | $2.83M | $3.59M | $2.65M | $2.13M | $1.75M | $2.21M | $1.54M | — | — | — | |
| $8.6M | — | — | — | — | — | — | — | — | — | — | — | $7.42M | $5.04M | $3.52M | $3.89M | $2.59M | — | — | — | |
| -$9.95M | -$9.95M | -$11.69M | -$21.44M | -$24.82M | -$24.54M | -$31.68M | -$23M | -$14.06M | -$5M | -$5.08M | -$8.54M | -$7.42M | -$4.9M | -$3.43M | -$3.91M | $2.4M | — | — | — | |
| -$81K | — | — | — | — | — | — | — | — | — | — | — | — | — | -$93K | $151K | $189K | — | — | — | |
| — | -$10.31M | -$11.62M | -$17.19M | -$24.28M | -$24.46M | -$31.81M | -$23.25M | -$13.95M | -$4.95M | -$4.98M | -$8.49M | -$9.25M | -$4.9M | -$3.43M | -$3.92M | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $5000 | $5000 | -$19K | — | — | — | |
| -$10.52M | -$10.31M | -$11.62M | -$17.19M | -$24.28M | -$24.46M | -$31.81M | -$23.25M | -$13.95M | -$4.95M | -$4.98M | -$8.49M | -$9.25M | -$4.9M | -$3.43M | -$3.92M | -$2.42M | -$1.78M | -$3.47M | -$6.24M | |
| USD/shares | -$0.86 | -$1.11 | -$2.31 | -$6.00 | -$9.90 | -$10.20 | -$16.05 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | -$0.86 | -$1.11 | -$2.31 | -$6.00 | -$9.90 | -$10.20 | -$16.05 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 9.27M | 5.02M | 2.87M | 2.43M | 2.41M | 1.99M | 1.46M | 1.33M | 1.25M | 1.24M | 1.23M | 910.85K | 715.88K | 9.17M | 8.01M | — | — | — | — |
| shares | — | 9.27M | 5.02M | 2.87M | 2.43M | 2.41M | 1.99M | 1.46M | 1.33M | 1.25M | 1.24M | 1.23M | 910.85K | 715.88K | 9.17M | 8.01M | — | — | — | — |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Operating lease liabilities | 2026-06-30 | USD 113,000 | 10-Q filed 2026-08-14 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Short-term borrowings | 2026-06-30 | USD 1,261,000 | 10-Q filed 2026-08-14 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 216 similar-size Biotechnology companies (of 532 listed).